Vigil Neuroscience Inc. has synthesized triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson's, Alzheimer's and Nasu-Hakola diseases.

Cajal Neuroscience Inc., a startup seeking new targets to use in medicines for neurodegeneration, has launched with the completion of a $96 million series A financing led by The Column Group and Lux Capital. The company, inspired by the pioneering work of Santiago Ramón y Cajal, is focused on the "mechanistic, spatial and temporal complexity of neurodegeneration" to determine "how, where and when different mechanisms contribute to disease."

Medshine Discovery Inc. and Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. have disclosed bicyclic substituted aromatic carboxylic acid compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.

Neuropn Therapeutics LLC has divulged piperidine urea derivatives as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of Parkinson's disease, pain, inflammation and neurodegeneration.

Nkgen Biotech Inc. has established a...

Shandong Luye Pharmaceutical Co. Ltd. has divulged cannabidiol prodrugs reported to be useful for the treatment of cancer, tremor, epilepsy, anxiety disorder, inflammatory disorders, pain, multiple sclerosis and Parkinson's disease, among others.

mPGES-1 is overexpressed in the dopaminergic neurons of the substantia nigra pars compacta of post-mortem brain tissue from patients with Parkinson’s disease (PD) as well as in 6-hydroxydopamine (6-OHDA)-injected PD mice.